Mesa Laboratories, Inc. MLAB R2KR3KTECH
Company Overview
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Why Investors Should Care
Revenue has grown at a 14.1% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $249.13M (+3.4% YoY); net profit $6.71M.
- Trailing 12 Months Year-on-year growth — revenue +1.0%, earnings -42.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.1%, profit CAGR 0.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.15% |
| 1 Year: | 1.00% |
Compounded Profit Growth
| 5 Years: | 0.55% |
| 1 Year: | -42.40% |
Stock Price Performance
| 1 Year: | +87.13% |
| 6 Months: | +31.71% |
| 3 Months: | +31.76% |
| 1 Month: | -6.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.65 · Neutral
P/E of 151.36 is above the sector median of 30.29 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 151.4.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Technology).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MLAB Mesa Laboratories, Inc. R2KR3KTECH | 128.66 | 151.36 | $719.96M | 0.50% | 5.06% | 2.66% | 14.15% | 0.55% |
| 2 | NVDA NVIDIA Corporation NDXSPXR3KAITECH | 210.96 | 26.64 | $5.09T | 0.46% | 74.66% | 117.21% | 24.64% | 32.12% |
| 3 | AAPL Apple Inc. NDXSPXR3KTECH | 347.72 | 39.88 | $5.07T | 0.32% | 68.72% | 148.75% | 1.81% | 3.92% |
| 4 | MSFT Microsoft Corporation NDXSPXR3KAITECH | 524.51 | 29.19 | $3.89T | 0.79% | 26.33% | 34.04% | 9.93% | 11.90% |
| 5 | TSM Taiwan Semiconductor Manufacturing Company Limited AITECH | 418.51 | 31.19 | $2.17T | 0.95% | 30.20% | 39.97% | 18.94% | 19.57% |
| 6 | AVGO Broadcom Inc. NDXSPXR3KAITECH | 321.68 | 41.08 | $1.54T | 0.72% | 16.70% | 44.25% | 17.04% | 54.08% |
| 7 | MU Micron Technology, Inc. NDXSPXR3KAITECH | 877.55 | 19.82 | $991.10B | 0.05% | 13.69% | 66.64% | 13.68% | 26.02% |
| 8 | AMD Advanced Micro Devices, Inc. NDXSPXR3KAITECH | 516.79 | 131.83 | $843.65B | 0.00% | 5.47% | 10.20% | 11.81% | 66.28% |
| 9 | ASML ASML Holding N.V. NDXAITECH | 1,571.80 | 51.02 | $603.73B | 0.50% | 42.97% | 53.94% | 15.55% | 19.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 25.14M | 24.86M | 26.68M | - | 26.29M | 25.54M | 31.66M | - | 29.94M | 31.86M | 34.17M | - | 34.92M | 35.84M | 54.70M | 50.45M | 58.75M | 54.29M | 50.65M | 53.16M | 53.47M | 58.17M | 57.83M | 62.84M | 59.54M | 60.74M | 65.13M | 60.14M |
| Gross Profit | 11.14M | 13.07M | 12.21M | 15.00M | 12.01M | 13.72M | 13.54M | 13.96M | 12.67M | 13.23M | 12.68M | 16.03M | 15.09M | 14.58M | 15.63M | 15.61M | 16.20M | 15.59M | 14.80M | 18.77M | 20.34M | 21.29M | 20.65M | 24.74M | 22.21M | 23.14M | 28.63M | 31.34M | 36.39M | 32.77M | 31.18M | 32.11M | 33.40M | 37.25M | 35.45M | 39.75M | 36.94M | 37.33M | 41.80M | 39.01M |
| Operating Income | 3.64M | 3.01M | 3.83M | - | 2.58M | 4.01M | 4.39M | - | 1.98M | 3.65M | -10.09M | - | 4.76M | 1.14M | 1.32M | - | 5.39M | 4.69M | -3.25M | - | 3.57M | 4.47M | 22.00K | - | 3.12M | 4.20M | -2.51M | -4.59M | 4.00M | 3.40M | -664.00K | -60.00K | -67.00K | 5.58M | 3.51M | 5.78M | 3.06M | 4.72M | 7.97M | 7.03M |
| Net Income | - | - | - | - | - | - | - | - | 1.52M | 2.35M | - | - | 4.23M | 994.00K | - | - | - | - | - | - | 1.22M | 2.68M | -4.54M | - | 2.00M | 3.72M | -2.06M | -1.44M | 1.31M | 451.00K | -549.00K | -1.23M | 2.12M | 3.39M | 3.43M | -1.68M | 4.74M | 2.48M | 3.63M | 2.83M |
| Diluted EPS | 0.74 | 0.48 | 0.69 | - | 0.51 | 0.62 | 0.84 | - | 0.39 | 0.60 | -2.93 | 1.08 | 1.06 | 0.25 | 0.21 | 0.34 | 1.14 | 0.73 | -1.03 | -0.37 | 0.26 | 0.51 | -0.89 | 0.74 | 0.38 | 0.70 | -0.39 | -0.27 | 0.24 | 0.08 | -0.10 | -0.23 | 0.39 | 0.62 | 0.63 | -0.31 | 0.85 | 0.45 | 0.65 | 0.49 |
| R&D Expense | 963.00K | 991.00K | 975.00K | - | 1.03M | 1.04M | 861.00K | - | 1.15M | 885.00K | 752.00K | - | 837.00K | 842.00K | 860.00K | - | 1.02M | 915.00K | 2.11M | - | 2.60M | 2.41M | 2.71M | - | 2.81M | 2.61M | 5.16M | 5.70M | 4.99M | 4.80M | 4.81M | 4.99M | 4.29M | 4.74M | 4.63M | 5.05M | 4.98M | 5.05M | 5.03M | 4.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.23M | 39.62M | 46.44M | 52.72M | 71.33M | 84.66M | 93.67M | 96.18M | 103.14M | 117.69M | 133.94M | 184.34M | 219.08M | 216.19M | 240.98M | 249.13M |
| Gross Profit | 19.57M | 23.51M | 28.86M | 31.69M | 43.39M | 51.41M | 53.24M | 54.62M | 60.92M | 65.36M | 87.01M | 109.09M | 133.69M | 133.25M | 150.87M | 158.27M |
| Operating Income | 9.86M | 12.48M | 13.10M | 11.79M | 15.86M | 16.32M | 16.31M | 2.18M | 9.78M | 7.92M | 12.36M | 4.70M | 3.32M | -272.07M | 16.34M | 18.51M |
| Net Income | 6.18M | 7.92M | 8.45M | 9.00M | 9.58M | 11.17M | 11.18M | -2.96M | 7.48M | 1.78M | 3.27M | 1.87M | 930.00K | -254.25M | -1.97M | 6.71M |
| Diluted EPS | 1.86 | 2.29 | 2.35 | 2.49 | 2.63 | 2.97 | 2.91 | -0.79 | 1.86 | 0.41 | 0.64 | 0.35 | 0.17 | -47.20 | -0.36 | 1.21 |
| R&D Expense | 1.44M | 1.36M | 2.01M | 2.32M | 3.29M | 3.97M | 4.16M | 3.54M | 3.51M | 6.36M | 10.39M | 15.77M | 20.49M | 19.30M | 19.52M | 20.31M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 50.56M | 50.70M | 65.92M | 97.53M | 117.32M | 160.75M | 171.73M | 164.10M | 156.77M | 409.11M | 601.48M | 707.37M | 661.83M | 446.80M | 433.35M | 427.75M |
| Total Equity | 31.20M | 36.42M | 43.91M | 52.75M | 64.33M | 73.48M | 84.68M | 97.82M | 99.36M | 111.31M | 220.01M | 406.23M | 393.80M | 393.48M | 145.39M | 159.83M | 186.25M |
| Cash & Equivalents | 10.47M | 3.55M | 7.19M | 4.01M | 5.58M | 2.03M | 5.70M | 5.82M | 5.47M | 10.19M | 81.38M | 263.87M | 49.35M | 32.91M | 28.21M | 27.32M | 26.93M |
| Long Term Debt | - | 1.50M | - | 4.00M | 16.50M | 23.25M | 42.25M | 53.67M | 44.63M | 20.61M | - | - | - | - | - | 71.25M | 67.50M |
| Total Liabilities | - | 14.14M | 6.78M | 13.17M | 33.20M | 43.84M | 76.07M | 73.91M | 64.74M | 45.46M | 189.09M | 195.25M | 313.57M | 268.35M | 301.40M | 273.52M | 241.50M |
| Current Liabilities | - | 9.93M | 4.26M | 4.66M | 10.21M | 14.66M | 23.97M | 16.57M | 17.29M | 23.66M | 26.01M | 32.58M | 48.05M | 43.36M | 44.31M | 163.96M | 61.90M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | 16.90M | 17.30M | 25.72M | 30.55M | 26.99M | 37.07M | - | 27.98M | 44.13M | 46.81M | 42.83M |
| Investing Cash Flow | - | - | - | - | - | -31.84M | -18.41M | -17.18M | -3.88M | -185.59M | -1.99M | - | -9.49M | -81.31M | -4.50M | -3.25M |
| Financing Cash Flow | - | - | - | - | - | 18.62M | 1.15M | -9.02M | -21.67M | 231.28M | 146.23M | - | -33.33M | 32.84M | -44.51M | -41.85M |
| Capital Expenditure | - | - | - | - | - | - | - | -2.80M | -1.26M | -1.50M | -1.99M | - | -4.54M | -2.57M | -4.50M | -3.25M |
| Free Cash Flow | - | - | - | - | - | - | - | 22.92M | 29.29M | 25.49M | 35.08M | - | 23.44M | 41.57M | 42.31M | 39.58M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -14.84M | -4.34M | -2.20M | -2.27M |
| Share Buybacks | 105.00K | 597.00K | 102.00K | 22.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | - | 1.99M | 2.18M | 2.30M | 2.35M | 2.41M | 2.46M | 2.72M | 3.17M | 3.34M | 3.41M | 3.45M | 3.47M | 3.52M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 57.2% | 59.3% | 62.2% | 60.1% | 60.8% | 60.7% | 56.8% | 56.8% | 59.1% | 55.5% | 65.0% | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| Operating Margin % | 28.8% | 31.5% | 28.2% | 22.4% | 22.2% | 19.3% | 17.4% | 2.3% | 9.5% | 6.7% | 9.2% | 2.6% | 1.5% | -125.9% | 6.8% | 7.4% |
| Net Margin % | 18.1% | 20.0% | 18.2% | 17.1% | 13.4% | 13.2% | 11.9% | -3.1% | 7.3% | 1.5% | 2.4% | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% |
| ROE % | 17.0% | 18.0% | 16.0% | 14.0% | 13.0% | 13.2% | 11.4% | -3.0% | 6.7% | 0.8% | 0.8% | 0.5% | 0.2% | -174.9% | -1.2% | 3.6% |
| ROCE % | 24.3% | 26.9% | 21.4% | 13.5% | 15.5% | 11.9% | 10.5% | 1.5% | 7.3% | 2.1% | 2.2% | 0.7% | 0.5% | -67.6% | 6.1% | 5.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Long Path Partners LP | 8.53% | 477.13K | $60.84M |
| 2 | Blackrock Inc. | 7.87% | 440.55K | $56.17M |
| 3 | Boston Partners | 4.74% | 265.15K | $33.81M |
| 4 | Vanguard Capital Management LLC | 4.24% | 237.46K | $30.28M |
| 5 | AQR Capital Management, LLC | 3.64% | 203.74K | $25.98M |
| 6 | Ranger Investment Management, L.p. | 3.11% | 173.99K | $22.19M |
| 7 | Morgan Stanley | 2.81% | 156.98K | $20.02M |
| 8 | Diamond Hill Capital Management Inc | 2.78% | 155.77K | $19.86M |
| 9 | Raymond James Financial, Inc. | 2.68% | 149.94K | $19.12M |
| 10 | Dimensional Fund Advisors LP | 2.65% | 148.40K | $18.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MLAB
Behavioral Patterns of MLAB and Institutional Flows - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNaEFMcGVRXzBYd2FtOG1nQ2ZtdkFwZUY5TmdMV1h2eDBQbDR1RVRSdHZnRWtmcmFQU1pUeXFmU3pfTTdHeEliellIVHBjRjdtbFJlSlNYck5ZNG01VFRsYjRDaC1ISDV1aWx5UGdjNGJCUGt5M25zcmpxUXhSMHRVRFk5LVZoNVgtWlE5en…
Mesa Laboratories Inc (MLAB) (Q1 2027) Earnings Call Highlights: Margin Expansion and Debt ... - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOY1l1M21lWXUzd2pYY01HVUE0MWhIN0paRU9TR2kyRkhyMm5ZWU93MHdrYjJLX3d6b2hnR2dTcVJqZHpkQ1A5VEYySnJzUWJtczVJVFRneFNCVHVtaTItWDlzSXhQVEFhSGFFd0pDV2tFTC1fUkd3OG9DOVN6YVFwM3hMOS05WmItVVRzZV…
Mesa Laboratories: Hard To Set The Right Diagnosis (NASDAQ:MLAB) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNM1BpV3o5WTR3aXpWR3ZSWV9JaXNuc1BYQ3Z2NjVjbF9rTGxIUjZDTDlibUx4S094ZEJBclVXcjY0WGJwaW9GVkUzYkxyMXZKdG1VN3V3Zk9FdXp4QXV4bUQxSU5uVVpMOHJQeEg4VmU4QWNlbHMtelk5aVMyM09veVhoUVl6WXZhYXVkQW…
MLAB Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBGRG9Sd3hlYm1aV3NnQloyRGwzTDdmVHZJb25CZ1BXd3JhNHBadUJKSW14SElwRUlGR3JVV1NqYmxHankyNmY1dXVYQzhwOU5fMjAtVDNhTGZkdWVDZkVzOGZ2S3ZWdmZRZFMwVVkyRUlGSE5VVW9EbDhR?oc=5" target="_blank">MLA…
Mesa Laboratories Keeps Quarterly Dividend at $0.16 per Share, Payable Dec. 15 to Holders of Record Nov. 30 - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQbUZRMVN6ejhTdkJlckZPRVR2SHJJSHQ3eG4tcFlwUzNyeEZORmhQRTRPNlNlRm04OV9TUGNSUHJvakhlbDB2YmRZbjVyWXdGZEZvRnh1ZVYyY25CM25ITXVPelVSTllucUFjZFNDMEhGZFNaeWpNeFR4cUFEbDFQQ2QxeFF5NGIxUzFyXy…
MESA LABORATORIES INC /CO/ ($MLAB) Former CEO and President 2026 Pay Revealed | MLAB Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxONHJZSXZwcTlIbFVaX3Fta3FSWFR6ZnpKclJzM2FSdmNDc3FnOGhYdkMxbXc1eDRwT0sxcF9PR1pqeTRIblBZX1JlTVJMeHFBbTJhNkZHM2pUSDZ3ZU9sRWNqU1B2YkxqSHpCSE94TUgzblJuUHdyVHZ1YU96VHZzLTJVQ0RYUkQ0b09TMF…
MLAB — Frequently Asked Questions
What is the current share price of Mesa Laboratories, Inc. (MLAB)?
As of 2026-10-23 16:27 PDT, Mesa Laboratories, Inc. (MLAB) trades at $128.66 on NasdaqGS. Its 52-week range is $59.15 to $142.23.
What is the market capitalisation of MLAB?
Mesa Laboratories, Inc. (MLAB) has a market capitalisation of $719.96M on NasdaqGS.
What is the P/E ratio of MLAB?
MLAB trades at a trailing price-to-earnings (P/E) ratio of 151.36. The industry average P/E is 30.29. Its price-to-book (P/B) ratio is 3.75.
Does MLAB pay a dividend?
Mesa Laboratories, Inc. (MLAB) currently offers a dividend yield of 0.50%.
What is the return on equity (ROE) of MLAB?
MLAB has a return on equity (ROE) of 2.66%. Its return on capital employed (ROCE) is 5.06%.
Is MLAB a good stock to buy?
This page provides a data-driven analysis of Mesa Laboratories, Inc. (MLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.